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Cancer multidrug resistance (MDR) occurs when cancer cells evade the cytotoxic actions of chemotherapeutics
through the active efflux of drugs from within the cells. Our group have previously demonstrated that
multidrug-resistant breast cancer cells spontaneously shed microparticles (MPs) and that these MPs can
transfer resistance to drug-responsive cells and confer MDR on those cells in as little as 4 h. Furthermore,
we also showed that, unlike MPs derived from leukaemia cells, breast cancerderived MPs display a tissue
selectivity in the transfer of P-glycoprotein (P-gp), transferring the resistance protein only to malignant breast
cells. This study aims to define the proteome of breast cancerderived MPs in order to understand the
differences in protein profiles between those shed from drug-resistant versus drug-sensitive breast cancer cells.
In doing so, we detail the protein cargo required for the intercellular transfer of MDR to drug-sensitive
recipient cells and the factors governing the transfer selectivity to malignant breast cells. We describe the
first proteomic analysis of MPs derived from human breast cancer cells using SDS PAGE and liquid
chromatographytandem mass spectrometry (LC/MS/MS), in which we identify 120 unique proteins found
only in drug-resistant, breast cancerderived MPs. Our results demonstrate that the MP-mediated transfer of
P-gp to recipient cells occurs alongside CD44; the Ezrin, Radixin and Moesin protein family (ERM); and
cytoskeleton motor proteins within the MP cargo.
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T
he major obstacle in the successful treatment of
breast cancer is the ability of tumour cells to resist
drugs through the acquisition of multidrug resis-
tance (MDR). MDR is a unique type of drug resistance
resulting in cross-resistance to a wide array of structurally
and functionally unrelated drugs following exposure to a
single chemotherapeutic (1). This capacity is attributed to
the overexpression of efflux proteins belonging to the ABC
superfamily of membrane transporters (2). Transporters re-
sponsible for MDR include P-glycoprotein (P-gp) (3) and
the multidrug resistanceassociated protein (MRP1) (4).
Cells communicate and exchange molecules with each
other either by direct cell-to-cell contact (5) or through the
dissemination of microvesicles, including microparticles
(MPs) (6), exosomes (7), apoptotic bodies (8), tunnelling
nanotubes (9) and/or filopodial bridges (10). During
intercellular communication, cells transfer nucleic acids
and proteins, which subsequently affect the phenotype
of the recipient cells (11). Our laboratory was the first to
show that P-gp can be disseminated within a cancer cell
population and acquired by drug-sensitive cells through
a process of intercellular binding and transfer mediated
by MPs (6,11,12). This mechanism allows for the inter-
cellular dissemination of cancer MDR both in vitro and
in vivo (13). Furthermore, we recently showed that breast
cancerderived MPs display a tissue selectivity in the
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transfer of P-gp, transferring the resistance protein to
malignant breast cells only (13).
MPs are small membrane vesicles arising from mem-
brane budding and are observed in most cell types during
apoptosis or upon cell activation (14). MPs serve an
important role in physiology, specifically in maintaining
haemostasis (15). They are also mediators in various dis-
ease states, including hypercoagulation and thromboem-
bolism (16), inflammation (17), diabetes (18), HIV-1 (19)
and cancer (20).
Interaction between proteins associated with the plasma
membrane and the cytoskeleton is crucial in cell adhesion,
cell signalling, membrane trafficking, cell motility, apop-
tosis and MP formation (2123). A family of closely
related proteins, the ERM (Ezrin, Radixin and Moesin)
proteins, play an extensive role in these processes and
possess a unique module required to interface and cross-
link membrane proteins with the cytoskeleton (21,23).
This research defines the proteome of breast cancer
derived MPs and compares the protein content of MPs
shed from drug-sensitive cells with their drug-resistant
counterparts. In doing so, we establish the protein cargo
required for the intercellular dissemination of MDR by
MPs and identify the protein signature associated with




The drug-sensitive human breast adenocarcinoma cell line
MCF-7 and the drug-resistant cell line MCF-7/Dx were
used in these studies. The cell lines have been validated as
appropriate models for the study of P-gp-mediated MDR
in vitro and in vivo (13). Cells were cultured in RPMI 1640
medium (Sigma-Aldrich), supplemented with 10% (v/v)
heat-inactivated foetal bovine serum (Life Technologies)
and maintained in the absence of antibiotics at 378C and
5% CO2.
Harvesting MPs
We have extensively described the isolation and validation
of the MP population for morphology, size and resistance
protein expression previously, using scanning electron
microscope (24,25) and flow cytometric analysis (FCM)
(6,13,2426). Likewise in this study, MPs were gated based
on size (Fig. 1). Thirty-four percent of the gated popula-
tion detected positive for P-gp expression using an anti-
body selective for the external epitope. This is consistent
with our previous findings for these MPs (13,25). The
procedure for isolation of MPs was as described by us in
Refs. (6,13,2426). In brief, after the cells have reached
confluence, the supernatant containing cells and MPs was
collected and centrifuged for 5 min at 500 g to remove cell
and cell debris. The supernatant was further centrifuged
for 5 min at 500 g and 1 h at 15,000 g at 178C to pellet MPs.
The pellet was washed in serum-free media and centri-
fuged for 2 min at 2,000 g to remove debris. The media
containing MPs were further centrifuged for 30 min at
18,000 g at 178C, and the pellet was resuspended in serum-
free RPMI-1640 and/or low-volume of alkaline extrac-
tion reagent (pH 8.8) containing 7 M urea, 2 M thiourea,
50 mM tris(hydroxymethyl)methylamine-HCl and 1%
C7BzO in a 10 mL final volume of water (27). MPs
resuspended in serum-free RPMI-1640 were validated by
FCM (LSRII, BD Biosciences, CA, USA) by P-gp (clone
17F9, BD Biosciences, Australia) staining as described
in Ref. (25).
Protein extraction
The pellet, resuspended in a low volume of alkaline
extraction, was sonicated 4 times for 30 sec at 40% power,
using a high-intensity ultrasonic processor (50 watt, Sonics
and Materials Inc., USA). The samples were reduced
and alkylated in the alkaline protein solution by adding
tributylphosphine solution to a final concentration of 5
mM (1:40 dilution) and acrylamide monomers to a final
concentration of 20 mM (1:50 dilution). The reaction was
quenched by adding 1 M dithiothreitol solution (final
concentration: 20 mM) and centrifuged at 17,000 g for
5 min to pellet any undissolved material. Finally, the pro-
tein was precipitated with 5 volumes of acetone before
resuspension in 1% SDS (sodium dodecyl sulphate). Total
protein concentration was determined using a Qubit fluo-
rometer (Invitrogen) as per the manufacturer’s protocol.
SDS-PAGE and trypsin in-gel digestion
One hundred micrograms of extracted MP proteins was
mixed with 2 SDS sample buffer containing Tris-HCl,
glycerol, SDS, bromophenol blue and water (pH 8.8) at
the ratio of 2:1 (proteinSDS buffer), and sonicated in a
water-bath for 5 min followed by centrifugation for 5 min
at 16,500 g, room temperature. Proteins were separated
using a 410% gel at a voltage of 150 V in MES SDS
running buffer (Invitrogen). The gel was fixed with 40%
methanol10% acetic acid for 30 min with gentle shaking
before staining with Coomassie blue overnight. In-gel
trypsin digestion was performed as described in Ref.
(27). Briefly, the gel (Supplementary file 1) was sectioned
according to the MW markers into 12 different sections,
and the sections diced into 11 mm pieces which were
then de-stained by adding 50% acetonitrile (ACN)
50 mM NH4HCO3 and incubating for 10 min at room
temperature. The process was repeated until the colour
disappeared. One hundred percent ACN was added
to dehydrate the gel pieces before rehydration with 12.5
ng/mL of trypsin solution (Trypsin gold-MS grade, Pro-
mega) and overnight incubation at 378C. After incubation,
the supernatant was collected after sonication in a water-
bath for 10 min, followed by another sonication after
the addition of 30 mL of 50% ACN2% formic acid.
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The solution was added to the previously collected
peptides, and the volume reduced to 15 mL by rotary
evaporation. The peptide solution was centrifuged at
14,000 g for 10 min to remove any insoluble material
prior to LC/MS/MS analysis.
Western blotting
Twenty micrograms of total cellular and MP proteins
were separated on SDS-PAGE, as described earlier, before
transferring to PVDF membrane (Pall Australia, VIC,
Australia). The membrane was blocked overnight with 5%
skim milk in PBS and 0.05% Tween 20, and then incubated
with anti-P-gp mAb (clone F4; Sigma-Aldrich), anti-Ezrin
mAb (clone 3C12; Life Science), anti-Moesin mAb (clone
38/87; Sigma-Aldrich), anti-radixin pAb (SAB2500859;
Sigma-Aldrich) or CD44 mAb (clone EPR1013Y; Abcam)
for 1 h. Anti-b-actin (clone AC-74; Sigma-Aldrich) was
used as the internal control, followed by horseradish
peroxidase conjugates secondary antibody. Protein ex-
pression was visualized using an ECL (enhanced chemo-
luminescence) system (Roche Applied Science, NSW,
Australia). The membranes were imaged using the lumi-
nescent image analyser LAS-3000 (Fujifilms, Brookvale,
NSW, Australia).
LC/MS/MS
Using an Eksigent AS-1 autosampler connected to a
Tempo nanoLC system (Eksigent, USA), 10 mL of the
sample was loaded at 20 mL/min with MS loading solvent
(2% ACN0.2% trifluoroacetic acid) onto a C8 trap
column (CapTrap, Michrom Biosciences, USA). After
washing the trap for 3 min, the peptides were washed off
the trap at 300 nL/min with MS solvent A (2% ACN
0.2% formic acid) onto a PicoFrit column (75150 mm,
New Objective) packed with Magic C18AQ resin (Mi-
chrom Biosciences). Peptides were eluted from the column
Fig. 1. Characterization of microparticles (MPs) isolated from MCF-7/Dx cells. a) MPs isolated from MCF-7/Dx cells were analysed
via flow cytometry and gated based on sized latex beads (0.31.1 mM); b) 34.4% of the gated MP population detected positive for P-gp
expression using anti-P-gp mAb (BD Bioscience). All experiments were repeated at least 3 times with similar results. Data are
representative of a typical experiment.
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and into the source of a QSTAR Elite hybrid quadrupole-
time-of-flight mass spectrometer (ABSciex) using the fol-
lowing program: 550% MS solvent B (98% ACN0.2%
formic acid) over 30 min, 5080% MS solvent B over 5 min,
80% MS solvent B for 2 min and 805% for 3 min. The
eluting peptides were ionized from the PicoFrit column at
2300 V. An Intelligent Data Acquisition (IDA) experiment
was performed, with a mass range of 3501,500 Da con-
tinuously scanned for peptides of charge state 25with
an intensity of more than 30 counts/s. Selected peptides
were fragmented, and the product ion fragment masses
measured over a mass range of 1001,500 Da. The mass of
the precursor peptide was then excluded for 15 sec.
Data analysis
Three biological replicates of total MP proteins were
analysed by LC-MS/MS, and the MS/MS data files
produced by the QSTAR Elite were searched using Mascot
Daemon (version 2.3, provided by the Walter and Eliza
Hall Institute, (28)) and searched against the LudwigNR
database (composed of the UniProt, plasmoDB and
Ensembl databases (vQ213)) with the following parameter
settings. Taxonomy: Homo sapiens. Fixed modifications:
none. Variable modifications: propionamide, oxidized
methionine and deamidated asparagine. Enzyme: semi-
trypsin. Number of allowed missed cleavages: 3. Peptide
mass tolerance: 100 ppm. MS/MS mass tolerance: 0.2 Da.
Charge state: 2, 3 and 4. Peptide identifications were
accepted if they could be established at greater than 95.0%
probability as specified by the Peptide Prophet algorithm
(29). Protein identifications were accepted if they could be
established at greater than 95.0% probability and con-
tained at least 2 identified peptides in 2 replicates. Protein
probabilities were assigned by the Protein Prophet algo-
rithm (30). Proteins that contained similar peptides and
could not be differentiated based on MS/MS analysis alone
were clustered by Scaffold to satisfy the principles of
parsimony.
Results and discussion
The production and secretion of extracellular vesicles
or MPs are universal cellular processes that have been
described in bacteria, archaea and eukaryotes (31,32).
MPs package proteins, DNA and RNA, and they display
a variety of cell surface markers. These features affect
how MPs identify target cells and the composition of the
cargo they transport to sites distal from their origin (33).
In higher eukaryotes, MPs have a range of pathophysio-
logical roles in cancer, infectious disease, systemic lupus,
arthritis and neurodegenerative disorders, and their pre-
sence has been detected in most body fluids (31,34).
Because of their informational content, MPs have been
described as signalosomes (31). MPs are involved in
tumour spread (35) and trigger tumour growth by
stimulating the proliferation of cancerous cells by inducing
angiogenesis in neighbouring endothelial cells (36). Pre-
vious work in our laboratory has shown for the first time
that purified MPs transfer functional P-gp from drug-
resistant cancer cells to drug-sensitive cells (6). We were
able to show that MPs can confer mRNA, which has
implications in the transfer and dominance of cancer traits
(11,24). In breast cancer, MPs show tissue selectivity by
transferring P-gp only to malignant breast cancer cells but
not to other cells (13). We set out to profile the proteome of
MPs derived from breast cancer cells to identify proteins
involved in MDR transfer. Thus, in this study, we applied a
conceptually unbiased proteomic approach to interrogate
the protein content of MPs purified from isogenic breast
cancerderived lines that differ in their resistance profile
from a broad range of drugs. Initially, more than 600
proteins were identified in both samples. Applying a
stringent criterion for protein validation of a minimum
of 2 peptides in at least 2 technical replicates reduced the
final analysis to 270 total proteins. Of the 270, 249 pro-
teins belong to MCF-7/Dx-MPs and 150 proteins belong
to MCF-7-MPs, with 129 common to both (Fig. 2,
Supplementary file 2). The unique proteins identified in
this experiment were also consistent with the Western blot
data shown in Fig. 3. We observed a selective packaging
of ERM and CD44 proteins in MCF-7/Dx-MPs relative
to MCF-7-MPs consistent with our LC-MS/MS data
(Table I). Our findings with ezrin are consistent with our
previous study that ezrin is present in MP cargo isolated
from resistant cells (13). In the context of breast cancer, the
selective packaging of these proteins in MCF-7/Dx-MPs
and not in MCF-7-MPs suggests that these cytoskeletal
elements are required in stabilizing P-gp in the MP cargo
en route to the recipient cells. This is consistent with
previous publications, which show a role for the FERM
domain-binding proteins and CD44 in P-gp membrane
localization (22,52). This finding expands our knowledge
of the required protein signature for P-gp transfer by MPs.
Fig. 2. Venn diagram depicting the comparison of proteins
identified in microparticles (MPs). Proteins identified in MPs
derived from drug-sensitive breast cancer cells (MCF-7) and
drug-resistant breast cancer cells (MCF-7/Dx).
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Gene ontology of the unique proteins identified from
drug-resistant MPs was generated according to their
annotated (a) cellular component, (b) biological process
and (c) molecular function. Besides protein profiling, our
interest was to identify candidate proteins that may con-
tribute to the ability of MPs to transfer MDR. The proteins
unique to drug-resistant cell MPs were investigated for
documented evidence of an association with P-gp and
enhancement of drug-resistant activity. Nineteen cytoske-
letal proteins, including vimentin, talin-1, coronin 1C and
members of the ERM family, were identified. KEGG
pathway analysis was able to classify 10 of the unique
proteins to the ‘‘regulation of actin cytoskeleton’’ pathway.
Those 10 proteins are myosin-9, vinculin, moesin,
actin 4, ezrin, integrin beta 3, fibronectin, ras-related C3
botulinum toxin substrate 1 (rho family), IQ motif con-
taining GTPase activating protein 1 and myosin light chain
12B regulatory protein. Most of the cytoskeletal-asso-
ciated proteins identified possess an N-terminally located
FERM domain (4.1 protein, Ezrin, Radixin and Moesin),
which plays a key role in linking actin fibres to the plasma
membrane. Forty-five proteins related to or known to
localize to the plasma membrane were also identified,
including multidrug-resistant protein 1, stomatin, amino-
peptidase, sarcoplasmicendoplasmic reticulum calcium
ATPase 2, ecto-5?-nucleotidase and glutathione S-trans-
ferase P1 (GSTP1). Ecto-5?-nucleotidase (CD73), a mem-
brane-associated glycoprotein that generates adenosine by
hydrolysing 5?-AMP to adenosine, has been implicated in
metastasis-promoting activities, including tumour angio-
genesis and vasodilation, adhesion of lymphocytes to
endothelial cells and adhesion, invasion and migration of
human breast cancer cells (38,53,54). Increased levels of
CD73 protein expression were reported in several MDR
cell lines, suggesting that this enzyme is involved in drug
resistance (39,55). Expression of various isoforms of
glutathione Stransferase P1 is enhanced in adenocarci-
noma cells during their transition to a drug-resistant state
(40). Involvement of these proteins is likely to play an
important role in intracellular trafficking of P-gp within
recipient cells because P-gp is localized not only in the
plasma membrane but also in intracellular compartments,
including the endoplasmic reticulum, golgi, endosomes
and lysosomes (56).
The FERM domain is found in a number of
cytoskeletal-associated proteins, including Band 4.1,
ezrin, radixin, moesin, DAL-1, talin-1, merlin, focal
adhesion kinase (FAK) and the proline-rich tyrosine
kinase 2 (PYK2) (41). This specialized group of macro-
molecules is found in higher order structures, including
sites of cellcell and cellextracellular matrix attachment
(42,57). Ezrin, radixin, moesin and talin-1 were found in
MPs derived from drug-resistant cells only. The N-
terminally located FERM domain binds to cytosolically
exposed C-terminal regions of integral membrane pro-
teins, and C-terminal domains in FERM proteins bind
actin (43,58). Interactions between the plasma membrane
and the cytoskeleton are essential in cell adhesion, cell
signalling, membrane trafficking, cell motility, apoptosis
and MP formation (2123). The presence of FERM
domain proteins in drug-resistant MPs indicates that
they are likely to play a key role in the mechanism by
which MPs transfer an MDR phenotype.
There are several key observations that support the
contention that MDR involves changes to cytoskeletal
structure. These include (a) the observation that MDR
Fig. 3. Western blot analysis of selectively packaged proteins in MCF-7-Dx-MPs (microparticles). Twenty micrograms of total cell and
MP lysates of drug-sensitive breast cancer cells (MCF-7) and drug-resistant breast cancer cells (MCF-7/Dx) were analysed by Western
blot to detect (a) P-glycoprotein, 170 kDa; (b) ezrin, 80 kDa; (c) moesin, 7880 kDa; (d) CD44, 82 kDa; and (e) radixin, 80 kDa.
Lanes 14 are MCF-7 cells, MCF-7-MPs, MCF-7/Dx cells, and MCF-7/Dx-MPs, respectively. b-actin (42 kDa) was used as the internal
control. Data are representative of a typical experiment.
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Table I. Unique proteins identified in drug-resistant microparticles, which are correlated with cancer and/or multidrug resistance
Protein description




protein coverage Function in relation to cancer and MDR
Multidrug-resistant 1/P-
glycoprotein (P-gp)
37 (33) 30 Energy-dependent efflux pump responsible for decreased
drug accumulation in multidrug-resistant cells (4).
CD44 12 (5) 25 Interacts with P-gp to promote cell migration and invasion
in cancer. Receptor for hyaluronic acid (HA). Mediates cell
cell and cellmatrix interactions through its affinity for HA,
and possibly also through its affinity for other ligands such
as osteopontin, collagens and matrix metalloproteinases
(MMPs). Adhesion with HA plays an important role in cell
migration, tumour growth and progression (37).
5?-nucleotidase 20 (18) 49 Promotes invasion, migration and adhesion of human
breast cancer cells. An increased level of protein
expression was found in several MDR cell lines, suggesting
the involvement of this protein in drug resistance (38,39).
Glutathione S-transferase P 9 (8) 66 Found to be abundantly expressed in mammalian tissues
that are associated with malignancies and play a role in
susceptibility to cancer (40).
Ezrin, Radixin and Moesin 34 (12)/11 (3)/7 (4) 43/17/14 Co-immunoprecipitates and co-localizes with P-gp, and
helps to interact plasma membrane with cytoskeleton.
Probably involved in connections of major cytoskeletal
structures to the plasma membrane. In epithelial cells,
required for the formation of microvilli and membrane
ruffles on the apical pole (22, 4143).
Aminopeptidase 30 (22) 36 Plays a role in tumour invasion and is found to be elevated
in plasma and effusion of cancer patients (44).
Fatty acid binding protein 6 (5) 58 Promotes cancer cell proliferation in hepatoma cells (45).
Talin-1, Vinculin 54 (23)/26 (21) 13/29 Talin 1 interacts with vinculin in order to help in cell
adhesion by mediating integrin-mediated adhesion (46).
Phosphoserine
aminotransferase
4 (4) 13 Stimulates cell growth and increases chemoresistance
of colon cancer cells (47).
Stathmin 3 (2) 27 Controls cell proliferation and participates in
carcinogenesis of various carcinomas. Involved in the
regulation of the microtubule (MT) filament system by
destabilizing microtubules. Prevents assembly and
promotes disassembly of microtubules (48).
Filamin 134 (61) 33 Promotes orthogonal branching of actin filaments and links
actin filaments to membrane glycoproteins. Anchors
various transmembrane proteins to the actin cytoskeleton
and serves as a scaffold for a wide range of cytoplasmic
signalling proteins. Interaction with FLNA may allow
neuroblast migration from the ventricular zone into the
cortical plate (49).
Alpha-actinin-4 41 (35) 50 Regulates the actin cytoskeleton and increases cellular
motility; its inactivation by transfer to the nucleus abolishes
the metastatic potential of human cancers (50).
Fermitin family homolog 2 6 (4) 10 Enhances integrin-mediated cell adhesion onto the
extracellular matrix and cell spreading (51).
Proteins identified from MPs derived from drug-resistant breast cancer cells, which are reported in the literature to directly or indirectly
contribute to cancer and/or MDR. The list is generated with the total unique peptide count and the protein coverage to determine the
percentage of the residues in each protein sequence.
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osteosarcoma cells exhibit an increase in actinstress
fibre organization which, when disrupted, sensitizes cells
to anticancer drugs (59); (b) P-gp translocates to the
plasma membrane and co-localizes with ezrin in IFN-g
treated, monocyte-derived macrophages (60); (c) the co-
localization of P-gp with ERM proteins occurs on
pseudopods and uropods in resistant lymphoid cells
(22), and disruption of the ERMP-gp association was
shown to impair P-gp function and resulted in the cellular
redistribution of P-gp (22); (d) an actinP-gp interaction is
essential for endosomal trafficking of P-gp (61); and (e)
P-gp binds ezrin at amino acid residues 149242 in the
FERM domain, and the disruption of this interaction
results in P-gp relocation from the plasma membrane to
the cytoplasm (62).
CD44, stathmin 1 and fermitin family homolog 2
(FERMT2) proteins were identified exclusively in MCF-
7/Dx-MPs. CD44 is the major surface receptor to hyalur-
onan and is implicated in cell adhesion, metastasis and
motility (63,64). C-terminal regions of CD44 located intra-
cellularly assemble with FERM domain proteins, includ-
ing ezrin, radixin and moesin, that anchor CD44 to actin
and influence downstream signalling pathways (37). The
ezrin binding site on CD44 has been mapped to 2 clusters
of basic amino acids in a membrane-proximal 9-amino-
acid region within the CD44 cytoplasmic domain (65).
CD44 and P-gp typically co-immunoprecipitate (52), their
expression in the cell is co-regulated (66) and both proteins
are found co-localized to the plasma membrane (52).
Supporting this model of interaction, it has recently been
proposed that P-gp complexes with activated CD44 via
ERM intermediates (67). Low-molecular-mass hyaluronic
acid promotes the internalization of the CD44ERM
protein complex, which is accompanied by decreased drug
resistance (37). These observations are supported by the
STRING database (Fig. 4), which shows P-gp interacting
with CD44 along with GSTP1, tropomyosin 3 and CD73.
CD44 also interacts with intercellular adhesion molecule
1 (ICAM 1), rho family, fibronectin 1, ezrin, moesin,
integrin beta 3, vinculin, basigin and vimentin. These
proteins have a role in promoting cancer cell prolifera-
tion and drug resistance. Vinculin modulates talin to help
in cell adhesion by mediating integrin-mediated adhesion
(46). Integrins are cell surface receptors that participate
in cellcell and cellextracellular matrix interactions and
contribute to the aggressive behaviour of cancer cells (68).
We found integrin-b-3 in resistant cell MPs, whereas
integrin-b-2 was present in both MP preparations. Integ-
rins are also known to transmit chemical signals and have
Table II. Pathway analysis of proteins unique to resistant breast cancerderived microparticles
GO_id Pathway Number of proteins p p-value fdr p-value Bonferroni
hsa03010 Ribosome 25 2.94 E24 6.23 E22 6.23 E22
hsa04810 Regulation of actin cytoskeleton 10 6.62 E4 7.02 E2 1.4 E1
hsa04510 Focal adhesion 8 8.54 E3 4.53 E1 1 E0
hsa04670 Leukocyte transendothelial migration 7 1.21 E3 8.55 E2 2.56 E1
hsa04520 Adherens junction 4 2.27 E2 9.65 E1 1 E0
Top 5 pathways were generated with the help of KEGG pathway analysis. Proteins related to regulation of actin cytoskeleton, focal
adhesion, ECMreceptor interaction and others were predicted to play a significant role in transferring p-gp and cause of drug resistance
in cells.
Fig. 4. Protein network generated from String 9.05. Network of
unique proteins associated with ABCB1/P-gp, isolated from
microparticles derived from drug-resistant breast cancer cell
(MCF-7/Dx), visualized on the String website. Proteins such as
CD44, tropomyosin 3, glutathione S-transferase P1 and ecto-5?-
nucleotidase are associated with drug-resistant proteins, whereas
fibronectin 1, intercellular adhesion molecule 1, ezrin, moesin,
integrin beta 3, vinculin, basigin, rho family and vimentin are
associated with CD44.
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a role in cellular responses such as migration, survival, dif-
ferentiation and motility (69). Besides vinculin and talin,
the kindlin family proteins also enhance integrin activa-
tion (70). FERMT2 proteins, which belong to the kindlin
family, were identified exclusively in MCF-7/Dx-MPs.
Other MCF-7/Dx-specific MP proteins identified in
our proteome analysis that have a role in promoting cancer
cell proliferation and drug resistance included stathmin,
aminopeptidase, phosphoserine aminotransferase and
other proteins listed in Table I. Stathmin has a role in cell
proliferation and participates in carcinogenesis of various
carcinomas (48), and aminopeptidases are reported to play
a role in tumour invasion and are found to be elevated in
the plasma and effusion of cancer patients (71), whereas
phosphoserine aminotransferase is reported to stimulate
cell growth and increases the chemotherapy resistance of
colon cancer cells (47).
Conclusion
Previously, we have reported that resistance to anticancer
drugs can be transferred by MPs from drug-resistant to
drug-sensitive cells within a cancer cell population
(6,11,12) in a tissue-selective manner (13). In this work,
we characterize the proteome of MPs derived from drug-
resistant versus drug-sensitive breast cancer cells and
show that the proteome of MCF-7/Dx-MPs has an abun-
dance of proteins previously reported to be involved in
MDR. These findings reinforce our earlier observations
and suggest that the transfer of MDR and specifically P-
gp to recipient cells is facilitated by cytoskeletal proteins,
actin binding proteins, glycolytic proteins, adhesion mol-
ecules and cytoskeletal motor proteins (Fig. 5, Table II).
These findings bring us closer to identifying targets,
which may be used in the design of selective therapeutics
for the prevention of MDR clinically.
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